Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2003
08/21/2003WO2002082075A3 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
08/21/2003WO2002064776A3 Signal transduction proteins 15b3, 15b3-1 and 15b3-2, and related dna sequences
08/21/2003WO2002064748A3 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
08/21/2003WO2002064731B1 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
08/21/2003WO2002062999A3 Proteins and nucleic acids encoding same
08/21/2003WO2002057452A3 Human proteins, polynucleotides encoding them and methods of using the same
08/21/2003WO2002046158A3 Piperidine/piperazine-type inhibitors of p38 kinase
08/21/2003WO2002044209A3 Cytonkine receptor zcytor19
08/21/2003WO2002040002A3 Method for modulation, stimulation, and inhibition of glutamate reuptake
08/21/2003WO2002036573A3 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
08/21/2003WO2002036162A3 Compositions for treatment of ocular neovascularization and neural injury
08/21/2003WO2002020722A9 Methods and compositions for in vitro targeting
08/21/2003WO2002020047A9 Chlamydial peptides and their mimics in demyelinating disease
08/21/2003WO2002002512A3 Compounds to treat alzheimer's disease
08/21/2003US20030159158 Method for identifying an agonist of neuronal calcium sensor-1 (NCS-1), for therapy of CNS disorders
08/21/2003US20030158424 Substituted alpha, beta-anellated butyrolactones
08/21/2003US20030158416 Neutralizing paroxetine hydrochloride in organic solvent, salt formation, crystallization or spray drying to form solvent-free
08/21/2003US20030158413 A thiochromane-7-carboxamide derivatives as Rho kinase enzyme inhibitor; nontoxic, anticancer agents
08/21/2003US20030158409 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
08/21/2003US20030158406 Enzyme inhibitor treating autoimmune diseases, Alzheimer's disease, atherosclerosis
08/21/2003US20030158398 Central nervous system disorders; psychological disorders
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158266 Particularly septic shock
08/21/2003US20030158262 Ameliorating progression of amyotrophic lateral sclerosis
08/21/2003US20030158242 Salt with a sugar substitute, especially saccharin, cyclamate or acesulfame.
08/21/2003US20030158239 Reacting a selenourea and an alpha-haloacyl halide in a solvent and in the presence of a catalyst; useful as raw materials for drugs and agricultural chemicals
08/21/2003US20030158238 Treating diseases such as cancer, inflammatory disorders, restenosis,
08/21/2003US20030158235 Pyridine amido derivatives
08/21/2003US20030158229 Also treating bulimia nervosa, irritable bowel syndrome, urinary incontinence, asthma, bradycardia, and bradyarrhythmia
08/21/2003US20030158225 Novel compounds
08/21/2003US20030158223 Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
08/21/2003US20030158222 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents)
08/21/2003US20030158219 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
08/21/2003US20030158217 Succinate and malonate complexes treatment of abnormal cell growth, such as cancer, and overexpression of erbB2, and inducing cell death
08/21/2003US20030158211 Methods and compositions for treatment of central nervous system disorders
08/21/2003US20030158209 Amidomethylcarbonyl-substituted piperazine derivatives containing additional amine groups, useful in treating eating, sexual and skin disorders
08/21/2003US20030158208 Dopamine D4 ligands for the treatment of novelty-seeking disorders
08/21/2003US20030158207 N-benzylpiperazine compounds
08/21/2003US20030158203 Triazolo-pyridazine derivatives as ligands for GABA receptors
08/21/2003US20030158202 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders
08/21/2003US20030158197 Certain alkylene diamine-substituted heterocycles
08/21/2003US20030158192 Activating cytokine biosynthesis, viricides treating a viral disease, antitumor agents, immunomodulators
08/21/2003US20030158187 Genetic polymorphisms in the preprotachy kinin gene
08/21/2003US20030158185 Novel use of phenylheteroakylamine derivatives
08/21/2003US20030158183 Method of treating schizophrenia
08/21/2003US20030158181 Method for treating cerebral ishaemia
08/21/2003US20030158175 Chroman derivatives as 5-hydroxytrytamine-6 ligands
08/21/2003US20030158173 NK 1 antagonists
08/21/2003US20030158170 1-oxo-1,2,3,4- tetrahydronaphtho(1,2-f)(1,4)thiazepine compounds for use as antidepressants treating anxiety, stress, eating disorders, bipolar disorder, schizophrenic and psychotic disorders
08/21/2003US20030158162 Administering a therapeutically effective amount of an epoxy-steroidal aldosterone receptor antagonist that contains a 9,11-epoxy group to the patient for reducing intraocular pressure
08/21/2003US20030158161 Administering to the human patient or non- human animal an effective amount of a substituted spirostan derivative to treat neurodegenerative disorders
08/21/2003US20030158147 Method for treating pain
08/21/2003US20030158146 Chemical compounds
08/21/2003US20030158099 Cancer therapy
08/21/2003US20030158096 Novel molecule
08/21/2003US20030157704 Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
08/21/2003US20030157649 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
08/21/2003US20030157648 Membrane binding polypeptides derived from urogenital and placenta tissue for monitoring and detecting modulators of ligand bind activity; drug screening
08/21/2003US20030157633 Comprises nucleotide sequences coding transmembrane protein/transport protein (TRPV3) for treating pain, inflammation and skin disorders
08/21/2003US20030157516 Medical diagnosis; binding with adenine
08/21/2003US20030157204 A plant extracts as immunomodulator treating autoimmune disorders, antiallergens treating hypersensitivity reactions; used as pharmaceuticals, cosmetics or dietary supplements
08/21/2003US20030157199 A mixtures of animal extracts, plant extracts used as antidepressants, cognition activators for learning enhancement, and treating rheumatism diseases; comprising curcumin, and cholic acid, or scymnol, and flavonoids
08/21/2003US20030157180 Suitable as depot formulation for administration via intramuscular or subcutaneous injection
08/21/2003US20030157177 In combination with a matrix vehicle selected from glycerol esters, hydrogenated oils, esterified polyethylene glycols, waxes and their mixtures
08/21/2003US20030157168 Comprises releasable opioid agonist (morphine); for prevention of abuse
08/21/2003US20030157167 Oxymorphone controlled release formulations
08/21/2003US20030157108 80-100% of the glycoprotein has a mature core carbohydrate structure which lacks fucose, attached to a Fc region
08/21/2003US20030157099 Human trk receptors and neurotrophic factor inhibitors
08/21/2003US20030157094 Prevention, therapy liver disorders, inflammatory bowel diseases, Crohn's disease; antiulcer agents; rheumatic diseases
08/21/2003US20030157084 Methods for preparing purified prostaglandin E synthase
08/21/2003CA2476553A1 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
08/21/2003CA2476292A1 Helical peptidomimetics
08/21/2003CA2476239A1 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003CA2476162A1 Jnk inhibitor
08/21/2003CA2475880A1 Novel tricycloimidazoline derivatives, method for production and use thereof as medicaments
08/21/2003CA2475838A1 Cytotoxic t-cell epitopes from chlamydia
08/21/2003CA2475783A1 Benzenesulfonamide derivatives as antipsychotic agents
08/21/2003CA2475763A1 Methods of treating attention deficit/hyperactivity disorder (adhd)
08/21/2003CA2475708A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003CA2475703A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003CA2475592A1 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
08/21/2003CA2475439A1 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
08/21/2003CA2475338A1 Treatment of ophthalmic disorders using urea and urea derivatives
08/21/2003CA2475102A1 Stabilized synthetic immunogen delivery systems
08/21/2003CA2473586A1 Treatment of sleep disorders using sleep target modulators
08/21/2003CA2472822A1 Chemical compounds
08/21/2003CA2472762A1 2-oxazolamines and their use as 5-ht2b receptor antagonists
08/21/2003CA2462688A1 Partial dopamine-d2 receptor agonist plus serotonin and/or noradrenaline inhibitor activity
08/21/2003CA2372785A1 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
08/20/2003EP1336600A2 Dimer-selective RXR modulators and methods for their use
08/20/2003EP1336409A1 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
08/20/2003EP1336406A1 Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
08/20/2003EP1335976A2 Modifier of organelle metalbolism
08/20/2003EP1335924A2 Ethers of 7-desmethylrapamycin for use in immunosuppression
08/20/2003EP1335923A2 Condensed pyridoindole derivatives
08/20/2003EP1335917A2 Condensed pyridoindole derivatives
08/20/2003EP1335916A1 Pyridyl-substituted triazoles as tgf inhibitors
08/20/2003EP1335915A2 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
08/20/2003EP1335907A1 Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
08/20/2003EP1335902A1 Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them
1 ... 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 ... 1833